CHOLANGIOCYTES IN HEALTH AND DISEASE:
FROM BASIC SCIENCE TO NOVEL TREATMENTS
9-11 JUNE 2017
OSLO, NORWAY

SCIENTIFIC ORGANISING COMMITTEE
Jesus M. Bañales, Spain
Peter Jansen, Netherlands
Nicholas F. LaRusso, United States
Marco Marzioni, Italy

PRELIMINARY* PROGRAMME

DAY I – Friday, 9 June 2017

13:30 – 14:00 Welcome and introductory remarks
Jesus M. Bañales, Spain
Peter Jansen, Netherlands
Nicholas F LaRusso, United States
Marco Marzioni, Italy

14:00 – 14:30 State-of-the-Art lecture
Cholangiocyte pathobiology: Past, present and future
Nicholas F LaRusso, United States

1. THE BILIARY TREE
   Chairs: Gianfranco Alpini, United States
   Joost Drenth, Netherlands

14:30 – 14:55 3D Anatomy of the biliary tree: Intravital two-photon based
functional imaging of bile salt transport in cholestasis -
pathophysiology of bile infarct formation
Jan Hengstler, Germany

14:55 – 15:20 Development of the biliary tree
Frederic Lemaigre, Belgium

15:20 – 15:45 Liver injury combined with inhibition of hepatocyte proliferation
leads ductular cells to function as facultative stem cells for
hepatocytes
Stuart Forbes, United Kingdom

15:45 – 16:10 Repopulating the biliary tree from the peribiliary glands
Robert Porte, Netherlands

*Subject to change
16:10 – 16:35  Bio-engineering the biliary tree  
Fortis Sampaziotis, United Kingdom

16:35 – 16:50  Coffee break

2. CHOLANGIOCYTE PATHOPHYSIOLOGY

Chairs: Marco Marzioni, Italy  
Michael Trauner, Austria

16:50 – 17:15  Animal models of biliary injury and altered bile acid metabolism  
Luca Fabris, Italy

17:15 – 17:40  Mechanisms of regulation of cholangiocyte response to injury  
Gianfranco Alpini, United States

17:40 – 18:05  Non-coding-RNAs and extracellular vesicles  
Jesus M. Bañales, Spain

18:05 – 18:30  Genetics and mechanisms of biliary cystogenesis: Impact in the clinical practice  
Joost Drenth, Netherlands

18:30 – 18:55  Pathogenesis and 3D structure of biliary fibrosis  
Massimo Pinzani, United Kingdom

19:00 – 20:00  Cocktail reception

DAY 2 – Saturday, 10 June 2017

3. BILE ACIDS AND THE BILIARY TREE: RECEPTORS AND BIOLOGICAL EFFECTS

Chairs: Jose J. G. Marin, Spain  
Gustav Paumgartner, Austria

08:30 – 08:55  Nuclear hormone receptors as drug targets  
Bart Staels, France

08:55 – 09:20  Gut and liver interactions  
Antonio Moschetta, Italy

09:20 – 09:45  TGR5 in physiology and disease  
Verena Keitel, Germany

09:45 – 10:10  Bile acids, FGF15/19 and liver regeneration: from mechanisms to clinical applications  
Matias Avila, Spain

10:10 – 11:00  Coffee break

4. CLINICAL CONSEQUENCES OF ALTERED BILE ACID METABOLISM

Chairs: Nicholas F. LaRusso, United States  
Peter Jansen, Netherlands

11:00 – 11:25  The molecular mechanism of cholestatic itch  
Ronald Oude Elferink, Netherlands

11:25 – 11:50  Heart and bile acids  
Catherine Williamson, United Kingdom

11:50 – 12:15  Bile acid-induced nephropathy  
Peter Fickert, Austria

*Subject to change
**12:15 – 13:45**

*Lunch and posters viewing*

---

**5. ORAL COMMUNICATIONS**

**Chairs:** Jesus M Banales, *Spain*
Ronald Oude Elferink, *Netherlands*

**13:45 – 15:00**

- *Young investigators – selected abstracts (5 communications)*
- *Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma*
  
  *Ander Arbelaiz, Spain*

**14:00 – 14:15**

- *The role of ageing in the pathophysiology of the biliary epithelium: identification of a molecular profile*
  
  *Luca Maroni, Italy*

**14:15 – 14:30**

- *Inhibition of Src tyrosine kinase restores CFTR function in cystic fibrosis cholangiocytes derived from human induced pluripotent stem cells (iPSC) and improves the response to CFTR potentiators and correctors used in therapy*
  
  *Romina Fiorotto, United States*

**14:30 – 14:45**

- *Chronic treatment with clinic dose of metformin completely reverses the epithelial to mesenchymal transition (EMT) in human intrahepatic cholangiocarcinomas (iCCAs) by activated AMPK / Foxo3a pathway*
  
  *Sabina Di Matteo, Italy*

**14:45 – 15:00**

- *The bile acid receptor TGR5 regulates paracellular permeability and protects the liver through an impact on the tight junction protein JAM-A*
  
  *Grégory Merlen, France*

---

**6. IMMUNITY IN THE BILIARY TREE**

**Chairs:** Jesus Prieto, *Spain*
Erik Schrumpf, *Norway*

**15:00 – 15:25**

- *Mucosal immunity of the biliary tree in normality and disease*
  
  *David Adams, United Kingdom*

**15:25 – 15:50**

- *How the biliary tree maintains immune tolerance*
  
  *Xiong Ma, China*

**15:50 – 16:15**

- *Bile acid homeostasis and immunity of the liver*
  
  *Christoph Schramm, Germany*

**16:15 – 16:40**

- *IgG4 cholangiopathy, a new entity*
  
  *Ulrich Beuers, Netherlands*

**16:40 – 17:10**

- *Coffee break*
7. **BILIARY CARCINOGENESIS**  
Chairs: Domenico Alvaro, *Italy*  
Matias Avila, *Spain*

17:10 – 17:35  
Target molecules in cholangiocarcinoma cells  
Gregory Gores, *United States*

17:35 – 18:00  
Stem cell origin of cholangiocarcinoma  
Tania Roskams, *Belgium*

18:00 – 18:25  
Chemoresistance and chemosensitization in cholangiocarcinoma  
Jose JG Marin, *Spain*

18:25 – 18:50  
Tumour stroma in cholangiocarcinoma - A novel therapeutic target  
Joachim Mertens, *Switzerland*

---

DAY 3 – Sunday, 11 June 2017

8. **MANAGEMENT ISSUES IN BILIARY DISORDERS**  
Chairs: Gregory Gores, *United States*  
Raoul Poupon, *France*

08:00 – 08:25  
Cholangiopathies in children  
Richard Thompson, *United Kingdom*

08:25 – 08:50  
Genetics of familial cholangiopathies  
Frank Lammert, *Germany*

08:50 – 09:15  
Cholangiocarcinoma: Epidemiological trends and clinical management  
Shahid Khan, *United Kingdom*

09:15 – 09:40  
The endoscopist and malignant and non-malignant biliary obstructions  
Stephen Pereira, *United Kingdom*

09:40 – 10:10  
Coffee break

---

9. **ROUNDTABLE: REDIRECTING THE MANAGEMENT OF BILIARY DISORDERS**  
Chairs: Ulrich Beuers, *Netherlands*  
Tom Karlsen, *Norway*

10:10 – 10:25  
Biomarkers for cholangiopathies and cholangiocarcinoma  
Daniel Gotthardt, *Germany*

10:25 – 10:40  
Assessment of hepatic secretion function with IIC-cholylsarcosine PET/CT  
Michael Soerenson, *Denmark*

10:40 – 10:55  
The future of therapy for cholangiopathies  
Michael Trauner, *Austria*

10:55 – 11:10  
Cholestatic drug induced liver injury  
Raul Andrade, *Spain*

11:10 – 11:25  
Cell transplantation

*Subject to change*
Domenico Alvaro, Italy

11:25 – 11:40  Endpoints in the designing clinical trials
Cyriel Ponsioen, Netherlands

11:40 – 11:55  Principles of value based medicine as applied to cholangiopathies
Mario Strazzabosco, Italy

11:55 – 12:45  Panel discussion
12:45 – 13:00  Concluding Remarks
13:00 – 14:00  Farewell Lunch